Basel, 24 May 2013
Roche Analyst Event at ASCO 2013
Analyst briefing on data presented at ASCO: Sunday, 2 June 2013
We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group’s oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago (31 May – 4 June 2013).
We will have a significant presence at the congress with more than 275 scientific abstracts submitted. A summary of the key data presented at ASCO will be provided at the Analyst briefing.
Venue: Marriott Downtown Chicago – Marriott Ballroom (4th floor), 540 North Michigan Avenue 60611 Chicago
Date: 2 June 2013
6:30pm to 8:00pm Central Daylight Time CDT (Chicago)
followed by a buffet reception
1:30am to 3:00am CEST (Switzerland) on Monday, 3 June 2013
0:30am to 2:00am BST (London) on Monday, 3 June 2013
To register for the event, please follow the link.
- Obinutuzumab (GA101) + chlorambucil (Clb) or rituximab (R) + Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and pre-existing medical conditions (comorbidities): final stage I results of the CLL11 (BO21004) phase 3 trial
Valentin Goede, MD, German CLL Study Group; Dept. I of Internal Medicine, University Hospital Cologne and Dept. of Geriatric Medicine and Research St. Marien-Hospital Cologne
- Oncology pipeline update
Hal Barron, MD, Chief Medical Officer and Head, Global Product Development
- Oncology business and strategy update
Daniel O’Day, COO Roche Pharmaceuticals Division
Dial in to the conference 10-15 min prior to the scheduled start using the following numbers:
+41 (0)58 310 5000 (Europe)
+44 (0)203 059 5862 (UK)
+1 (1)866 291 4166 (USA - Toll-Free)
Alternatively a live audio webcast can be accessed via http://ir.roche.com. The presentation slides will be available from the IR website at http://ir.roche.com following to the closure of the ASCO meeting.
A replay of the conference call will be available as of 8:00am CEST/7:00am BST on 3 June for 48 hours. Access is by dialing:
+41 (0)91 612 4330 (Europe)
+44 (0)207 108 6233 (UK)
+1 (1)866 416 2558 (USA)
and will be asked to enter the ID 14827 followed by the # sign.
In addition, we have prepared an ASCO planner providing an overview of oral and poster abstracts relevant to Roche, including indication of time and venue of the respective presentations at the congress. This planner can be downloaded from our website via http://www.roche.com/asco_planner_2013.pdf.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.
In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.